Commentary Outrage of the Month: Opioid Maker Executives “No Better Than Street-Level Drug Dealers” December 1, 2017
Press Releases Trump Declares Opioid Public Health Emergency, But It Will Take More Than Tweets and Big Pharma Nominations to Save Lives October 26, 2017
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding A New Extended-Release Oxycodone Product July 26, 2017
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding Reformulated Opana ER March 14, 2017
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees Regarding Extended-Release Morphine Sulfate (Arymo) August 4, 2016
Commentary Outrage of the Month: Congress Finds Money for Big Pharma, but Not Opioid-Addicted Patients August 1, 2016
Letters, Testimony & Filings Letter to U.S. Congress Conference Committee for the Comprehensive Addiction and Recovery Act July 1, 2016
Letters, Testimony & Filings Testimony Before the FDA’s Drug Safety and Risk Management Committee and Anesthetic and Analgesic Drug Products Advisory Committee Regarding ALO-02 (Oxycodone/Naltrexone) June 8, 2016